Frederic Millot
Overview
Explore the profile of Frederic Millot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millot F, Ampatzidou M, Roy Moulik N, Tewari S, Elhaddad A, Hammad M, et al.
Leukemia
. 2025 Mar;
PMID: 40044960
The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs)....
2.
Berlanga P, Aerts I, Corradini N, Ndounga-Diakou L, Entz-Werle N, Ducassou S, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(2):e31449.
PMID: 39558828
SACHA-France (NCT04477681) is a prospective real-world study that collects clinical safety and efficacy data of novel anticancer therapies prescribed off-label or on compassionate use to patients <25 years. From March...
3.
Domenech C, Kicinski M, De Moerloose B, Piette C, Chahla W, Kornreich L, et al.
Hemasphere
. 2024 Nov;
8(11):e70025.
PMID: 39540141
Here, we report the results of the prospective cohort study EORTC-CLG 58081 and compare them to the control arm of the randomized phase 3 trial EORTC-CLG 58951, on which treatment...
4.
Bobin C, Iddir Y, Butterworth C, Masliah-Planchon J, Saint-Charles A, Bellini A, et al.
Clin Cancer Res
. 2024 May;
30(15):3316-3328.
PMID: 38787533
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell-specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a...
5.
Pincez T, Fernandes H, Fahd M, Pasquet M, Abou Chahla W, Granel J, et al.
Am J Hematol
. 2024 Apr;
99(7):1269-1280.
PMID: 38651646
Refractory chronic immune thrombocytopenia (r-cITP) is one of the most challenging situations in chronic immune thrombocytopenia (cITP). Pediatric r-cITP is inconsistently defined in literature, contributing to the scarcity of data....
6.
Raiser P, Schleiermacher G, Gambart M, Dumont B, Defachelles A, Thebaud E, et al.
Eur J Cancer
. 2024 Mar;
202:114001.
PMID: 38489858
Background: Addition of anti-GD2 antibodies to temozolomide-based chemotherapy has demonstrated increased antitumor activity and progression-free survival in patients with relapsed/progressive high-risk neuroblastoma. However, chemo-immunotherapy is not yet approved for this...
7.
de Ville de Goyet M, Kicinski M, Suciu S, Vandecruys E, Uyttebroeck A, Ferster A, et al.
Discov Oncol
. 2024 Jan;
15(1):20.
PMID: 38285235
Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and...
8.
Demoor-Goldschmidt C, Veillon P, Esvan M, Leonard M, Chauvet S, Bertrand A, et al.
BMC Cancer
. 2024 Jan;
24(1):130.
PMID: 38267891
Background: Treatment summaries and a personalized survivorship care plans based on internationally approved, organ-specific follow-up care recommendations are essential in preserving the health and quality of life for cancer survivors....
9.
Granel J, Fernandes H, Bader-Meunier B, Guth A, Richer O, Pillet P, et al.
Blood
. 2024 Jan;
143(16):1576-1585.
PMID: 38227934
Autoimmune cytopenia (AIC) in children may be associated with positive antinuclear antibodies (ANA) and may progress to systemic lupus erythematosus (SLE). We evaluated the risk of progression to SLE of...
10.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, et al.
Blood Adv
. 2023 Sep;
7(23):7279-7289.
PMID: 37738125
The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in...